Dyadic International (DYAI) Receivables - Accured (2024 - 2026)

Dyadic International (DYAI) posted Receivables - Accured of $12423.0 for Q1 2026, down 64.64% sequentially from $35129.0 in Q4 2025.

Dyadic International (DYAI) Receivables - Accured (2024 - 2026) Analysis & Trends

Dyadic International has reported Receivables - Accured for 3 years, with the latest figure at $12423.0 in Q1 2026.

Quarterly Receivables - Accured changed N/A year-over-year to $12423.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12423.0 (changed N/A YoY) and the FY2025 annual result came in at $35129.0, up 44.87% from the prior year.
Receivables - Accured eased to $12423.0 in Q1 2026 per DYAI's latest filing, from $35129.0 in the prior quarter.
Over five years, Receivables - Accured peaked at $35129.0 in Q4 2025 and troughed at $12423.0 in Q1 2026.
A 3-year average of $23933.3 and a median of $24248.0 in 2024 frame the typical range for Receivables - Accured.
The widest YoY moves for Receivables - Accured: up 44.87% in 2025, down 44.87% in 2025.
Over 3 years, Receivables - Accured stood at $24248.0 in 2024, then jumped by 44.87% to $35129.0 in 2025, then slumped by 64.64% to $12423.0 in 2026.
According to Business Quant data, Receivables - Accured over the past three periods registered $12423.0, $35129.0, and $24248.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables - Accured (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Dyadic International	19.98 Mn	19.98 Mn	-	12,423.00

Download Data